These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8565695)

  • 1. [Study of autologous bone marrow transplantation in the treatment of gynecologic carcinoma].
    Tu C; Meng Y; Lin Y
    Zhonghua Fu Chan Ke Za Zhi; 1995 Aug; 30(8):475-8. PubMed ID: 8565695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tandem high-dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma.
    Lotz JP; Bouleuc C; André T; Touboul E; Macovei C; Hannoun L; Lefranc JP; Houry S; Uzan S; Izrael V
    Cancer; 1996 Jun; 77(12):2550-9. PubMed ID: 8640705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.
    Gadducci A; Landoni F; Sartori E; Maggino T; Zola P; Gabriele A; Rossi R; Cosio S; Fanucchi A; Tisi G
    Gynecol Oncol; 2001 May; 81(2):150-9. PubMed ID: 11330942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study].
    Shi Y; Pan F; Han X
    Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel-based chemotherapy in carcinoma of the fallopian tube.
    Gemignani ML; Hensley ML; Cohen R; Venkatraman E; Saigo PE; Barakat RR
    Gynecol Oncol; 2001 Jan; 80(1):16-20. PubMed ID: 11136563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose cyclophosphamide, etoposide and carboplatin with autologous bone marrow support for metastatic breast cancer: long-term results.
    Baker WJ; Vukelja SJ; Burrell LM; Lee N; Perry JJ
    Bone Marrow Transplant; 1998 Apr; 21(8):775-8. PubMed ID: 9603400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage therapy for recurrent and refractory ovarian cancer with high-dose chemotherapy and autologous bone marrow support: a Gynecologic Oncology Group pilot study.
    Broun ER; Belinson JL; Berek JS; McIntosh D; Hurd D; Ball H; Williams S
    Gynecol Oncol; 1994 Aug; 54(2):142-6. PubMed ID: 8063237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.
    Bitran JD; Samuels B; Klein L; Hanauer S; Johnson L; Martinec J; Harris E; Kempler J; White W
    Bone Marrow Transplant; 1996 Feb; 17(2):157-62. PubMed ID: 8640160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
    Peppercorn J; Herndon J; Kornblith AB; Peters W; Ahles T; Vredenburgh J; Schwartz G; Shpall E; Hurd DD; Holland J; Winer E
    Cancer; 2005 Oct; 104(8):1580-9. PubMed ID: 16118805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support.
    Winer EP; Lindley C; Hardee M; Sawyer WT; Brunatti C; Borstelmann NA; Peters W
    Psychooncology; 1999; 8(2):167-76. PubMed ID: 10335560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
    Valteau-Couanet D; Vassal G; Pondarré C; Bonnay M; Benhamou E; Couanet D; Plantaz D; Hartmann O
    Bone Marrow Transplant; 1996 Apr; 17(4):485-9. PubMed ID: 8722343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results in non randomized patients with acute myelogenous leukemia: a single institution experience.
    Deliliers GL; Annaloro C; Oriani A; Della Volpe A; Boschetti C; Cortelezzi A; Maiolo AT
    Ann Ital Med Int; 1998; 13(3):146-51. PubMed ID: 9859570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
    Visani G; Lemoli R; Tosi P; Martinelli G; Testoni N; Ricci P; Motta M; Gherlinzoni F; Leopardi G; Pastano R; Rizzi S; Piccaluga P; Isidori A; Tura S
    Bone Marrow Transplant; 1999 Sep; 24(5):467-72. PubMed ID: 10482929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
    Prince HM; Rischin D; Quinn M; Allen D; Planner R; Neesham D; Gates P; Davison J
    Gynecol Oncol; 2001 May; 81(2):216-24. PubMed ID: 11330952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer.
    Gisselbrecht C; Extra JM; Lotz JP; Devaux Y; Janvier M; Peny AM; Guillevin L; Bremond D; Delain M; Herbrecht R; Lepage E; Maraninchi D
    Bone Marrow Transplant; 1996 Nov; 18(5):857-63. PubMed ID: 8932837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
    Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S
    Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a phase I clinical trial.
    Stiff PJ; Bayer R; Tan S; Camarda M; Sosman J; Peace D; Kinch L; Rad N; Loutfi S
    Clin Cancer Res; 1995 Dec; 1(12):1495-502. PubMed ID: 9815949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS).
    Bernbeck B; Bahci S; Meisel R; Troeger A; Schönberger S; Laws HJ; Kramm C; Wessalowski R; Koscielniak E; Dilloo D; Göbel U
    Klin Padiatr; 2007; 219(6):318-22. PubMed ID: 18050041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and low toxicity of early radiotherapy after high-dose chemotherapy and autologous stem cell transplantation for patients with high-risk stage II-III and locally advanced breast carcinoma.
    Stemmer SM; Pfeffer MR; Rizel S; Hardan I; Goffman J; Gezin A; Neumann A; Kitsios P; Alezra D; Brenner HJ
    Cancer; 2001 Jun; 91(11):1983-91. PubMed ID: 11391576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.